✨ Free AI Report
Agentix Corp.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Agentix Corp.
Company Research

Agentix Corp.: Business Overview, Financials & Competitive Analysis

Agentix Corp. scores 3/10 on the AskCyborg Cyborg Score (Challenged). High-risk preclinical biotech with unproven endocannabinoid therapeutics competing against established pharma players; suitable only for venture/speculation portfolios. Agentix is a pre-revenue, clinical-stage biotech with minimal operating infrastructure. OTC-traded status, no reported employees, and a highly speculative pipeline without Phase 1/2 clinical trial data materially limit commercial readiness and investor confidence.

What is Agentix Corp.'s industry? Agentix Corp. (agentixcorp.com) operates in Pharmaceuticals. AskCyborg classifies Agentix Corp. under Pharmaceuticals in its company registry.

Agentix Corp is a biotechnology company engaged in developing novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. The company's principal b...

3/ 10Challenged

Cyborg Score thesis

High-risk preclinical biotech with unproven endocannabinoid therapeutics competing against established pharma players; suitable...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest Agentix Corp. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Agentix Corp.

AskCyborg analysts argue the bull and bear cases for Agentix Corp. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Agentix Corp. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Agentix Corp. Overview

Pro stress-test →

Agentix Corp is a biotechnology company engaged in developing novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. The company's principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and drive innovations in the endocannabinoid space.

Strategic Profile

Pro stress-test →

The company is focused on developing synthetic agonists, inverse agonists, and antagonists which modulate the endocannabinoid system (ECS). Its pipeline includes AGTX-2004, a CB1 receptor antagonist demonstrated efficacy in animal models of obesity and type 2 diabetes, and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist with efficacy in animal models of obesity and non-alcoholic fatty liver disease. The company is in clinical-stage development with limited near-term revenue visibility.

Competitive Landscape

Pro stress-test →

Agentix competes in the metabolic disease and endocannabinoid therapeutic space against established pharmaceutical companies with robust pipelines and regulatory experience. Direct competitors include larger biotech and pharma companies developing CB1 modulators and obesity/diabetes treatments. The company's peripheral-acting CB1 approach attempts to differentiate from first-generation systemic cannabinoid compounds, though clinical validation remains early-stage.

Industry Context

Agentix Corp. operates in Pharmaceuticals.

Key facts

Founded: 2013 (incorporated); rebranded June 2019 · Headquarters: Dana Point, California, US · Employees: 0-1 reported · Revenue: Estimated <$5M (private development stage)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Agentix Corp..

  • Clinical-stage biopharmaceutical company focusing on peripheral-acting CB1 receptor antagonists/inverse agonists for metabolic diseases (Type 2 diabetes, obesity, NAFLD, NASH); pipeline includes AGTX-2004 and AGTX-2003.
  • Pre-revenue development stage entity with zero employees as of September 2020; utilizes consultants including CEO Rudy Mazzocchi; no meaningful commercial revenue generated.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2021Worldwide exclusive license and services agreement with RTI International
  • January 2022Discussed 2022 clinical development efforts and potential NASDAQ uplisting with The Stock Day Podcast
Get alerted when Agentix Corp. has a new material development →

Compare Agentix Corp. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Agentix Corp. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Agentix Corp.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Agentix Corp. and its top competitor on Cyborg Score”
“What did Agentix Corp. do this quarter?”
“Is Agentix Corp. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Agentix Corp. do?+
Agentix Corp is a biotechnology company engaged in developing novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. The company's principal b...
What is Agentix Corp.'s Cyborg Score?+
Agentix Corp. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Agentix Corp.'s main competitors?+
The full competitive landscape for Agentix Corp. is in the AskCyborg report.
How can I get the full Agentix Corp. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Agentix Corp. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Agentix Corp. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual